Success Metrics

Clinical Success Rate
73.3%

Based on 11 completed trials

Completion Rate
73%(11/15)
Active Trials
0(0%)
Results Posted
100%(11 trials)
Terminated
4(21%)

Phase Distribution

Ph phase_2
2
11%
Ph phase_1
5
26%
Ph phase_3
1
5%
Ph not_applicable
2
11%
Ph phase_4
6
32%

Phase Distribution

5

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
5(31.3%)
Phase 2Efficacy & side effects
2(12.5%)
Phase 3Large-scale testing
1(6.3%)
Phase 4Post-market surveillance
6(37.5%)
N/ANon-phased studies
2(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.3%

11 of 15 finished

Non-Completion Rate

26.7%

4 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(11)
Terminated(4)
Other(4)

Detailed Status

Completed11
Terminated4
unknown4

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
73.3%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (31.3%)
Phase 22 (12.5%)
Phase 31 (6.3%)
Phase 46 (37.5%)
N/A2 (12.5%)

Trials by Status

terminated421%
unknown421%
completed1158%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT02711826Phase 1

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Completed
NCT04066114Phase 1

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Completed
NCT03468478Phase 4

Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation

Completed
NCT02123108Phase 4

Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation

Completed
NCT00403416Phase 1

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

Completed
NCT02974686Phase 4

Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

Terminated
NCT03678987

Mycophenolate Mofetil Pharmacokinetics in Systemic Sclerosis

Completed
NCT01570348Phase 2

Crohn's Allogeneic Transplant Study

Terminated
NCT01053221Phase 2

Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation

Terminated
NCT02328963Phase 4

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A

Completed
NCT01473732Not Applicable

Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity

Terminated
NCT00622895Phase 1

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

Completed
NCT01336296Phase 4

Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients

Completed
NCT01625377Phase 3

A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients

Completed
NCT01309022

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

Unknown
NCT02435368

The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear

Unknown
NCT02036554Phase 4

Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients

Unknown
NCT00997412Not Applicable

Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis

Unknown
NCT00128947Phase 1

Pharmacokinetics of Mycophenolate Mofetil in Healthy Volunteers

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19